The UK and US have announced a major commercial pact that will preserve no import taxes on UK drug exports entering the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to increase spending on medicines through the National Health Service (NHS). This commitment guarantees that duties on these crucial products will stay at nothing for a duration of 36 months.
This development comes after earlier warnings to significantly raise tariffs on branded drug imports, with potential rates floated as high as one hundred percent.
"This agreement between the UK strengthens the global environment for cutting-edge drugs and brings much-needed equity to transatlantic medicine commerce," an announcement noted.
Economic Importance
Drugs represent one of the the United Kingdom's most significant export categories to the US, which is by far the biggest destination for major companies like GSK and AstraZeneca.
Trade data show that in the one-year period prior to September, the UK shipped pharmaceutical products totaling billions to the US. This amount represented 17.4% of all goods exports in that timeframe.
"This guarantee secures employment, boosts funding and facilitates the UK to become a worldwide center for medical research," a minister commented.
Detailed NHS Changes
The deal involves several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to raise total public funding on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at 15%. Last year, refunds exceeded twenty percent.
Broader Context
This agreement takes place against a long-running dispute between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
This friction were exacerbated by claims that US consumers were charged a premium for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar investments have been directed toward American operations.
One official stated that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a proportion of its total funding over the previous ten-year period.
